Baird 'Incrementally Positive' on Intercept (ICPT) on NDA/MAA filing for OCA in PBC

Baird analyst Brian Skorney reiterated an Outperform rating and $344 price target on Intercept Pharmaceuticals (NASDAQ: ICPT), saying they are incrementally positive on NDA/MAA filing for OCA in PBC.

Skorney commented, "Although the PBC indication has become the red-headed stepchild to NASH, we believe the submission to both major global regulatory agencies should create some enthusiasm around shares given the selloff following the announcement of REGENERATE Phase 3 design."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $240.39 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Barclays Reiterates Equalweight Rating on Crown Castle (CCI)
• Marsh & McLennan (MMC) PT Raised to $221 at Evercore ISI